GeneDx Holdings Corp. (WGS) Surged Following Strong Earnings and Improved Guidance

Core Insights - Polen Capital's fourth-quarter investor letter for the Polen 5Perspectives Small Growth Strategy reported a gross return of -1.3% and a net return of -1.5% for the portfolio, contrasting with a 1.2% return from the Russell 2000 Growth Index [1] - The small-cap asset class is gaining attention due to declining interest rates and improving earnings growth, with a notable focus on biotech stocks [1] - The strategy's name change emphasizes the importance of a multi-perspective approach in investing [1] Company Highlights - GeneDx Holdings Corp. (NASDAQ:WGS) is a genomics company specializing in genetic testing services, which has seen a significant year-over-year increase in testing volumes and improved insurance reimbursement rates [3] - As of February 23, 2026, GeneDx Holdings Corp. had a market capitalization of $2.52 billion, with a one-month return of -16.97% and a 52-week loss of 8.34% [2] - GeneDx is not among the 30 most popular stocks among hedge funds, although its holdings increased from 34 to 39 in the last quarter [4]